

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF

Art Unit: 1609

DENT ET AL.

Examiner: Webb, Walter E.

APPLICATION NO: 10/527,553

FILED: SEPTEMBER 9, 2005

FOR: COMBINATION OF A) N-{5-[4-(4-METHYL-PIPERAZINO-METHYL)-
BENZOYL-LAMIDO]-2-METHYLPHENYL}-4-(3-PYRIDYL)-2-
PYRIMIDINE-AMINE AND B) A HISTONE DEACETYLASE
INHIBITOR FOR THE TREATMENT OF LEUKEMIA

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

PETITION FOR EXTENSION OF TIME

Sir:


The Office Action of May 23, 2008 has a shortened statutory time set to expire on August 23, 2008. A three-month extension is hereby requested pursuant to 37 CFR §1.136(a).

Please charge Deposit Account No. 19-0134 in the name of Novartis in the amount of \$1110 for payment of the extension fee. An additional copy of this paper is here enclosed. The Commissioner is hereby authorized to charge any additional fees under 37 CFR §1.17 which may be required, or credit any overpayment, to Account No. 19-0134 in the name of Novartis.

Novartis
Pharma Intellectual Property
One Health Plaza, Building 101
East Hanover, NJ 07936-1080

Date: November 19, 2008

Respectfully submitted,



George R. Dohmann
Attorney for Applicants
Reg. No. 33,593
Phone No. (862) 778-7824